[KSCI] Korea Science Citation Index Service

7-Oxostaurosporine Selectively Inhibits the Mycelial Form of Candida albicans

Hwang, Eui-Il (Bio Research Group, KT&G Central Research Institute)
Yun, Bong-Sik (Laboratory of Cellular Function Modulator, Korea Research Institute of Bioscience and Biotechnology)
Lee, Sang-Han (Laboratory of Cellular Function Modulator, Korea Research Institute of Bioscience and Biotechnology)
Kim, Soo-Kie (Department of Microbiology, Wonju College of Medicine, IFBB, Yonsei University)
Lim, Se-Jin (College of Pharmacy, Dongduk Women's University)
Kim, Sung-Uk (Laboratory of Cellular Function Modulator, Korea Research Institute of Bioscience and Biotechnology)

Publication Information

Journal of Microbiology and Biotechnology / v.14, no.5, 2004 , pp. 1067-1070 More about this Journal

Abstract

In the course of screening for specific inhibitors against the mycelial form of Candida albicans from natural resources, we have isolated and identified A6792-1 from Streptomyces sp. A6792 by using several chromatographies. By spectral analyses, this compound was determined as 7-oxostaurosporine, having a structure of staurosporine aglycon noiety. 7-Oxostaurosporine exhibited a selective growth inhibitory activity against the mycelial form of Candida spp. up to $100\mu\textrm{g}/disc$ in bioassay. It also exhibited a specific antifungal activity against the mycelial form of Candida spp. including C. krusei, C. albicans, C. tropicalis, and C. lusitaniae with MICs ranging from 3.1 to $25\mu\textrm{g}/ml$ 7-Oxostaurosporine demonstrated no in vivo toxicity in SPF ICR mice. Therefore, this compound may have a considerable potential as an antifungal agent based on the preferential inhibition against growth of the mycelial form of Candida spp., dimorphic fungi.

Keywords

Candida albicans; morphological transition; 7-oxostaurosporine;

Citations & Related Records

Times Cited By Web Of Science : 3 (Related Records In Web of Science)

Reference

1	Calderone, R. A. and W. A. Fonzi. 2001. Virulence factors of Candida albicans. Trends Microbial. 9(7): 327- 335.
2	Cassone, A. 1986. Cell wall of pathogenic yeasts and implications for antimycotic therapy. Drugs Exptl. Clin. Res. 12: 635- 643.
3	Milewaki, S., H. Chmara, and E. Borowaki. 1983. Growth inhibitory effect of antibiotic tetaine on yeast and mycelial forms of Candida albicans. Arch. Microbial. 135: 130- 136.
4	Odds, F. C. 1988. Candida and Candidosis. 2nd Ed. Balliere Tindall, London.
5	Koshino, H., H. Osada, and K. Isono. 1992. A new inhibitor of protein kinase C, RK-1409 (7-oxostaurosporine). II. Fermentation, isolation, physico-chemical properties and structure. J. Antibiotics 45(2): 195- 198.
6	Osada, H., H. Koshino, T. Kudo, R. Onose, and K. Isono. 1992. A new inhibitor of protein kinase C, RK-1409 (7oxostaurosporine). I. Taxonomy and biological activity. J. Antibiotics 45(2): 189- 194.
7	Lo, H. J., J. R. Kohler, B. DiDomenico, D. Loebenberg, A. Cacciapuoti, and G. R. Fink. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90: 939- 949.
8	Omura, S., Y. Sasaki, Y. Iwai, and H. Takeshima. 1995. Staurosporine, a potentially importantgiftfrom a microorganism. J. Antibiotics 48(7): 535- 548.
9	Gullo, V., L. Gunnarsson, V. Hegde, A. Horan, D. Loebenberg, J. Marquez, M. Petel, M. Pular, and J. Schwartz. 1991. A novel antifungal from an actinomadurae with preferential activity against the mycelial phase of Candida albicans. J. Ind. Microbial. 8: 65- 68.
10	Lorian, V. 1986. Antibiotics in Laboratory Medicine. 2nd Ed. Williams & Wilkins, Baltimore.